[HTML][HTML] Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis …
…, EJ Andreu, E Ornilla, EM Villarón… - Journal of translational …, 2016 - Springer
Background Mesenchymal stromal cells are a promising option to treat knee osteoarthritis.
Their safety and usefulness must be confirmed and the optimal dose established. We tested …
Their safety and usefulness must be confirmed and the optimal dose established. We tested …
[HTML][HTML] Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification
…, N López-Holgado, FM Sánchez-Guijo, E Villarón… - Experimental …, 2008 - Elsevier
OBJECTIVE: Optimization of the mesenchymal stem cells (MSC) isolation and expansion
method. MATERIALS AND METHODS: Mononuclear cells (MNC) from bone marrow aspirates …
method. MATERIALS AND METHODS: Mononuclear cells (MNC) from bone marrow aspirates …
Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome
…, JL Garcia, FM Sanchez-Guijo, C Robledo, EM Villarón… - Leukemia, 2009 - nature.com
The presence of cytogenetic aberrations on mesenchymal stem cells (MSC) from myelodysplastic
syndrome (MDS) patients is controversial. The aim of the study is to characterize bone …
syndrome (MDS) patients is controversial. The aim of the study is to characterize bone …
Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation
EM Villaron, J Almeida, N López-Holgado… - …, 2004 - haematologica.org
BACKGROUND AND OBJECTIVES: Whether human mesenchymal stem cells (MSC) can be
transplanted is controversial and their presence in peripheral blood is not fully accepted. In …
transplanted is controversial and their presence in peripheral blood is not fully accepted. In …
[HTML][HTML] Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis …
…, M del Consuelo del Cañizo, EM Villarón… - Journal of translational …, 2018 - Springer
Background Mesenchymal stromal cells (MSCs) are a promising option to treat knee
osteoarthritis (OA). Their safety and usefulness have been reported in several short-term clinical …
osteoarthritis (OA). Their safety and usefulness have been reported in several short-term clinical …
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
…, N López-Holgado, P Maiso, M Alberca, E Villarón… - Blood, 2006 - ashpublications.org
We explored the ability of the proteasome inhibitor bortezomib, which prevents nuclear
factor κB (NF-κB) activation, to block T-cell activation, proliferation, and survival within …
factor κB (NF-κB) activation, to block T-cell activation, proliferation, and survival within …
[HTML][HTML] Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with …
JF Blanco, EM Villarón, D Pescador, C da Casa… - Stem cell research & …, 2019 - Springer
Background Posterolateral spinal fusion with autologous bone graft is considered the “gold
standard” for lumbar degenerative disc disease (DDD) when surgical treatment is indicated. …
standard” for lumbar degenerative disc disease (DDD) when surgical treatment is indicated. …
[HTML][HTML] Optimization of mesenchymal stromal cell (MSC) manufacturing processes for a better therapeutic outcome
…, M Lopez-Parra, E Villarón… - Frontiers in …, 2022 - frontiersin.org
MSCs products as well as their derived extracellular vesicles, are currently being explored
as advanced biologics in cell-based therapies with high expectations for their clinical use in …
as advanced biologics in cell-based therapies with high expectations for their clinical use in …
[HTML][HTML] Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
…, J Pueyo, R Cordovilla, E Villaron… - ERJ Open …, 2021 - Eur Respiratory Soc
Rationale Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal
cells (MSCs) have shown benefit in other inflammatory diseases. Objectives To evaluate the …
cells (MSCs) have shown benefit in other inflammatory diseases. Objectives To evaluate the …
[HTML][HTML] Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial
V Gomez-Ruiz, JF Blanco, EM Villarón… - Stem Cell Research & …, 2023 - Springer
Posterolateral spinal fusion is the standard surgical approach for patients with degenerative
disc disease. In our previously published article, we reported a 5-years follow-up of a phase I…
disc disease. In our previously published article, we reported a 5-years follow-up of a phase I…